234 related articles for article (PubMed ID: 26718727)
1. Genetic characterization of early onset ovarian carcinoma.
Bernards SS; Norquist BM; Harrell MI; Agnew KJ; Lee MK; Walsh T; Swisher EM
Gynecol Oncol; 2016 Feb; 140(2):221-5. PubMed ID: 26718727
[TBL] [Abstract][Full Text] [Related]
2. Inherited Mutations in Women With Ovarian Carcinoma.
Norquist BM; Harrell MI; Brady MF; Walsh T; Lee MK; Gulsuner S; Bernards SS; Casadei S; Yi Q; Burger RA; Chan JK; Davidson SA; Mannel RS; DiSilvestro PA; Lankes HA; Ramirez NC; King MC; Swisher EM; Birrer MJ
JAMA Oncol; 2016 Apr; 2(4):482-90. PubMed ID: 26720728
[TBL] [Abstract][Full Text] [Related]
3. New germline mutations in BRCA1, ATM, MUTYH, and RAD51D genes in Tuvans early-onset breast cancer patients.
Gervas P; Molokov A; Ivanova A; Panferova Y; Kiselev A; Chernyshova A; Pisareva L; Choynzonov E; Cherdyntseva N
Exp Oncol; 2021 Mar; 43(1):52-55. PubMed ID: 33785725
[TBL] [Abstract][Full Text] [Related]
4. Mutations in 12 genes for inherited ovarian, fallopian tube, and peritoneal carcinoma identified by massively parallel sequencing.
Walsh T; Casadei S; Lee MK; Pennil CC; Nord AS; Thornton AM; Roeb W; Agnew KJ; Stray SM; Wickramanayake A; Norquist B; Pennington KP; Garcia RL; King MC; Swisher EM
Proc Natl Acad Sci U S A; 2011 Nov; 108(44):18032-7. PubMed ID: 22006311
[TBL] [Abstract][Full Text] [Related]
5. Gene panel sequencing in familial breast/ovarian cancer patients identifies multiple novel mutations also in genes others than BRCA1/2.
Kraus C; Hoyer J; Vasileiou G; Wunderle M; Lux MP; Fasching PA; Krumbiegel M; Uebe S; Reuter M; Beckmann MW; Reis A
Int J Cancer; 2017 Jan; 140(1):95-102. PubMed ID: 27616075
[TBL] [Abstract][Full Text] [Related]
6. Detection of Germline Mutations in Patients with Epithelial Ovarian Cancer Using Multi-gene Panels: Beyond BRCA1/2.
Eoh KJ; Kim JE; Park HS; Lee ST; Park JS; Han JW; Lee JY; Kim S; Kim SW; Kim JH; Kim YT; Nam EJ
Cancer Res Treat; 2018 Jul; 50(3):917-925. PubMed ID: 29020732
[TBL] [Abstract][Full Text] [Related]
7. Prevalence of deleterious germline variants in risk genes including BRCA1/2 in consecutive ovarian cancer patients (AGO-TR-1).
Harter P; Hauke J; Heitz F; Reuss A; Kommoss S; Marmé F; Heimbach A; Prieske K; Richters L; Burges A; Neidhardt G; de Gregorio N; El-Balat A; Hilpert F; Meier W; Kimmig R; Kast K; Sehouli J; Baumann K; Jackisch C; Park-Simon TW; Hanker L; Kröber S; Pfisterer J; Gevensleben H; Schnelzer A; Dietrich D; Neunhöffer T; Krockenberger M; Brucker SY; Nürnberg P; Thiele H; Altmüller J; Lamla J; Elser G; du Bois A; Hahnen E; Schmutzler R
PLoS One; 2017; 12(10):e0186043. PubMed ID: 29053726
[TBL] [Abstract][Full Text] [Related]
8. Identification of germline genetic mutations in patients with pancreatic cancer.
Salo-Mullen EE; O'Reilly EM; Kelsen DP; Ashraf AM; Lowery MA; Yu KH; Reidy DL; Epstein AS; Lincoln A; Saldia A; Jacobs LM; Rau-Murthy R; Zhang L; Kurtz RC; Saltz L; Offit K; Robson ME; Stadler ZK
Cancer; 2015 Dec; 121(24):4382-8. PubMed ID: 26440929
[TBL] [Abstract][Full Text] [Related]
9. UK consensus recommendations for clinical management of cancer risk for women with germline pathogenic variants in cancer predisposition genes:
Hanson H; Kulkarni A; Loong L; Kavanaugh G; Torr B; Allen S; Ahmed M; Antoniou AC; Cleaver R; Dabir T; Evans DG; Golightly E; Jewell R; Kohut K; Manchanda R; Murray A; Murray J; Ong KR; Rosenthal AN; Woodward ER; Eccles DM; Turnbull C; Tischkowitz M; ; Lalloo F
J Med Genet; 2023 May; 60(5):417-429. PubMed ID: 36411032
[TBL] [Abstract][Full Text] [Related]
10. About 1% of the breast and ovarian Spanish families testing negative for BRCA1 and BRCA2 are carriers of RAD51D pathogenic variants.
Gutiérrez-Enríquez S; Bonache S; de Garibay GR; Osorio A; Santamariña M; Ramón y Cajal T; Esteban-Cardeñosa E; Tenés A; Yanowsky K; Barroso A; Montalban G; Blanco A; Cornet M; Gadea N; Infante M; Caldés T; Díaz-Rubio E; Balmaña J; Lasa A; Vega A; Benítez J; de la Hoya M; Diez O
Int J Cancer; 2014 May; 134(9):2088-97. PubMed ID: 24130102
[TBL] [Abstract][Full Text] [Related]
11. Germline and somatic mutations in homologous recombination genes predict platinum response and survival in ovarian, fallopian tube, and peritoneal carcinomas.
Pennington KP; Walsh T; Harrell MI; Lee MK; Pennil CC; Rendi MH; Thornton A; Norquist BM; Casadei S; Nord AS; Agnew KJ; Pritchard CC; Scroggins S; Garcia RL; King MC; Swisher EM
Clin Cancer Res; 2014 Feb; 20(3):764-75. PubMed ID: 24240112
[TBL] [Abstract][Full Text] [Related]
12. Frequency of Germline Mutations in 25 Cancer Susceptibility Genes in a Sequential Series of Patients With Breast Cancer.
Tung N; Lin NU; Kidd J; Allen BA; Singh N; Wenstrup RJ; Hartman AR; Winer EP; Garber JE
J Clin Oncol; 2016 May; 34(13):1460-8. PubMed ID: 26976419
[TBL] [Abstract][Full Text] [Related]
13. [The French Genetic and Cancer Consortium guidelines for multigene panel analysis in hereditary breast and ovarian cancer predisposition].
Moretta J; Berthet P; Bonadona V; Caron O; Cohen-Haguenauer O; Colas C; Corsini C; Cusin V; De Pauw A; Delnatte C; Dussart S; Jamain C; Longy M; Luporsi E; Maugard C; Nguyen TD; Pujol P; Vaur D; Andrieu N; Lasset C; Noguès C;
Bull Cancer; 2018 Oct; 105(10):907-917. PubMed ID: 30268633
[TBL] [Abstract][Full Text] [Related]
14. Germline variants in DNA repair genes associated with hereditary breast and ovarian cancer syndrome: analysis of a 21 gene panel in the Brazilian population.
da Costa E Silva Carvalho S; Cury NM; Brotto DB; de Araujo LF; Rosa RCA; Texeira LA; Plaça JR; Marques AA; Peronni KC; Ruy PC; Molfetta GA; Moriguti JC; Carraro DM; Palmero EI; Ashton-Prolla P; de Faria Ferraz VE; Silva WA
BMC Med Genomics; 2020 Feb; 13(1):21. PubMed ID: 32039725
[TBL] [Abstract][Full Text] [Related]
15. Germline and somatic mutations of multi-gene panel in Chinese patients with epithelial ovarian cancer: a prospective cohort study.
Li W; Shao D; Li L; Wu M; Ma S; Tan X; Zhong S; Guo F; Wang Z; Ye M
J Ovarian Res; 2019 Aug; 12(1):80. PubMed ID: 31472684
[TBL] [Abstract][Full Text] [Related]
16. Recommendations for Preventive Care for Women with Rare Genetic Cause of Breast and Ovarian Cancer.
Foretová L; Navrátilová M; Svoboda M; Vašíčková P; Sťahlová EH; Házová J; Kleiblová P; Kleibl Z; Macháčková E; Palácová M; Petráková K
Klin Onkol; 2019; 32(Supplementum2):6-13. PubMed ID: 31409076
[TBL] [Abstract][Full Text] [Related]
17. Targeted massively parallel sequencing of a panel of putative breast cancer susceptibility genes in a large cohort of multiple-case breast and ovarian cancer families.
Li J; Meeks H; Feng BJ; Healey S; Thorne H; Makunin I; Ellis J; ; Campbell I; Southey M; Mitchell G; Clouston D; Kirk J; Goldgar D; Chenevix-Trench G
J Med Genet; 2016 Jan; 53(1):34-42. PubMed ID: 26534844
[TBL] [Abstract][Full Text] [Related]
18. Frequency of mutations in a large series of clinically ascertained ovarian cancer cases tested on multi-gene panels compared to reference controls.
Lilyquist J; LaDuca H; Polley E; Davis BT; Shimelis H; Hu C; Hart SN; Dolinsky JS; Couch FJ; Goldgar DE
Gynecol Oncol; 2017 Nov; 147(2):375-380. PubMed ID: 28888541
[TBL] [Abstract][Full Text] [Related]
19. Mutation Analysis of the RAD51C and RAD51D Genes in High-Risk Ovarian Cancer Patients and Families from the Czech Republic.
Janatova M; Soukupova J; Stribrna J; Kleiblova P; Vocka M; Boudova P; Kleibl Z; Pohlreich P
PLoS One; 2015; 10(6):e0127711. PubMed ID: 26057125
[TBL] [Abstract][Full Text] [Related]
20. Simultaneous germline and somatic sequencing in ovarian carcinoma: mutation rate and impact on clinical decision-making.
Jorge S; McFaddin AS; Doll KM; Pennington KP; Norquist BM; Bennett RL; Pritchard CC; Swisher EM
Gynecol Oncol; 2020 Mar; 156(3):517-522. PubMed ID: 31883735
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
